Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 97–120 of 245
Sex-Specific Biology Reshapes Longevity Medicine
Healthcare systems designed around male physiology as default have created parallel blind spots for both women and men, undermining the personalization claims central to longevity medicine. Addressing sex-specific biology, diagnostic gaps, and equitable access is foundational to advancing longevity outcomes across populations.
Wellness Must Adopt Evidence Standards to Meet Longevity Demand
The wellness industry must evolve from aspiration-based claims to evidence-informed practice as consumers increasingly demand measurable healthspan outcomes, biomarker transparency, and scientific rigor. This structural shift toward mainstream longevity science creates both opportunity and accountability for an industry historically adjacent to rather than embedded in clinical prevention.
Capital deployment shapes longevity medicine's path to clinic
The seventh Longevity Investors Conference convenes leading geroscientists, entrepreneurs, and institutional investors in Gstaad to examine which longevity therapies will attract capital and reach clinical deployment. The event reflects the sector's maturation from early-stage hypothesis generation toward translational execution and scaled healthcare integration.
Forever Healthy Releases AI4L 1.0 for Practical Longevity
Forever Healthy released AI4L 1.0, an open-source system using Audit-Driven Prompting to generate evidence-based reviews of longevity interventions with live citation verification and zero-tolerance quality gates. This addresses the scalability problem of evaluating a fragmented landscape of senolytic, metabolic, and peptide-based therapies where evidence is dispersed across journals and clinical trials.
Inside the race to build longevity-ready business models
Business models built on traditional three-stage life assumptions are becoming obsolete as longevity reshapes market demand across leisure, housing, beauty, and healthcare sectors. Organizations that embed healthspan optimization and address demographic health disparities position themselves to capture significant commercial opportunity while improving population health outcomes.
GPER Agonist Enters Rigorous Aging Validation Framework
LNS8801, a GPER-activating drug candidate from Linnaeus Therapeutics, has entered the National Institute on Aging's Interventions Testing Program—one of the most rigorous preclinical validation systems in longevity science. This milestone reflects a maturation in aging research: the field now prioritizes healthspan preservation alongside lifespan extension, moving beyond simple longevity metrics to functional capacity and disease resilience.
Updating risk models with real-world data
Longevity AI and Meir Medical Center are updating classical cardiovascular and metabolic disease risk models using contemporary real-world clinical data to improve early detection accuracy. This approach prioritizes practical prevention of the diseases causing the largest population-level health loss, rather than pursuing experimental aging interventions.
The hidden bottleneck in longevity biotech
Longevity biotech's bottleneck lies not in laboratory science but in financial infrastructure—fragmented systems and delayed data visibility cause promising therapies to be shelved despite scientific merit. Unified financial platforms that integrate clinical, operational, and budgetary data in real time can accelerate therapeutic development by improving allocation decisions and reducing administrative friction.
Why the wellness industry needs a new operating system
The wellness industry operates on infrastructure designed for episodic experiences rather than sustained behavioral change over decades. Longevity now requires systems-based approaches that embed healthy behaviors into everyday environments and social contexts, not temporary interventions delivered in specialized settings.
Amazon makes longevity move with Lifeforce collab
Amazon One Medical has integrated Lifeforce's biomarker analysis into its primary care platform, offering members personalized health insights derived from over 50 standard lab biomarkers organized by health domains. This integration represents a significant expansion of preventive medicine tools into mainstream primary care, positioning biomarker-driven interpretation as a foundational element of personalized health management.
XPRIZE Healthspan: Functional Recovery Trials Begin
XPRIZE Healthspan has advanced 20 finalists to clinical trials within its $101 million competition, with ten teams receiving $1 million each to test interventions targeting age-related decline in muscle, cognitive, and immune function. The transition from preclinical promise to coordinated human trials represents a critical inflection point: therapeutic mechanisms now must demonstrate measurable functional restoration in adults aged 50–90 within one year.
Evidence Infrastructure Closes Longevity Interpretation Gap
Evipedia provides structured, regularly updated evidence reviews for over 500 health and longevity interventions, addressing a critical infrastructure gap in the longevity field. As intervention options proliferate faster than reliable evaluation frameworks, this resource helps practitioners and consumers distinguish established evidence from speculative claims.
Spain's longevity advantage: 85.7 years and rising
The International Longevity Summit Madrid 2026 will convene leading scientists, physicians, and entrepreneurs in Spain, a country with the highest life expectancy in the EU. The event positions Madrid as a center for advancing longevity science and healthy aging research at the institutional level.
Estrogen Receptor Agonist Advances to Federal Lifespan Testing
LNS8801, a selective estrogen receptor agonist developed by Linnaeus Therapeutics, has been selected for lifespan testing by the National Institute on Aging's Interventions Testing Program, with concurrent federal funding to evaluate its effects on functional capacity and age-related decline. The drug's progression from oncology trials to dedicated longevity research reflects emerging evidence that certain receptor pathways may influence both disease prevention and healthspan preservation.
Data without decisions: Why biomarkers alone fail
Wearable technology and biomarker testing provide detailed health data, but information alone does not drive behavior change. Effective health optimization requires prioritized decision-making and strategic intervention selection, not data accumulation.
Loyal raises $100m Series C to advance canine longevity drug
Loyal secured $100 million Series C funding to advance LOY-002, a prescription medication designed to extend healthy lifespan in senior dogs by targeting metabolic pathways associated with aging. The drug has completed enrollment in its pivotal clinical trial and represents a potential first-in-species FDA-authorized longevity therapeutic.
20/20 BioLabs expands longevity test with kidney risk tech
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.
ARPA-H pours millions into healthspan-focused human trials
ARPA-H is allocating $144 million through its PROSPR program to fund seven research teams testing interventions designed to extend healthspan in humans. The initiative addresses a critical gap in geroscience drug development by establishing early biomarkers and trial designs that can demonstrate functional benefit within one to three years rather than decades.
Digital Engagement and Successful Aging: A Longitudinal Analysis of Older Adults in China
Digital engagement demonstrates bidirectional associations with successful aging in Chinese adults aged 60–75 over seven years, with baseline digital use predicting improvements in physical function, cognitive performance, and subjective well-being, while successful aging outcomes also predict sustained digital engagement. This longitudinal evidence suggests digital literacy and consistent technology use function as modifiable factors supporting multiple dimensions of aging outcomes.
Serotonin Anti-Aging Center to open Lake Nona location this spring
Serotonin Anti-Aging Centers is expanding to Lake Nona, Florida in spring 2026, adding to its national footprint of longevity and hormone optimization clinics. The expansion reflects growing consumer demand for preventive wellness services, though the article focuses on business development rather than clinical evidence.
Indigenous Ageing and the Structural Roots of Longevity Gaps
A Lancet Healthy Longevity editorial marking the International Day of the World's Indigenous Peoples examines the persistent lifespan and healthspan disparities affecting an estimated 476 million Indigenous people across 90 countries. It attributes these shared adversities to common histories of colonialism and dispossession that removed ancestral lands and disrupted cultural identity, and calls for ageing research and services shaped by Indigenous communities themselves.
Longevity Outcomes Depend on System Integration, Not Innovation Supply
Canada's transition to super-aged status by 2026 has prompted institutional action on longevity as a structural challenge rather than a future concern. Manulife and the World Economic Forum are launching an innovation challenge focused on three interconnected dimensions—healthy aging, financial resilience, and social connection—with emphasis on solutions that integrate into existing systems rather than operating parallel to them.
SIRIO Europe rolls out new habit-first longevity platform
SIRIO Europe launched Aeion, a habit-first longevity platform that prioritizes consistent daily rituals over complex protocols, addressing the persistent gap between longevity innovation and real-world adoption. The platform delivers eight supplement concepts through friction-reducing formats designed to support energy, mobility, cardiovascular function, and inflammatory aging management.
Revive expands access to physical therapy via Orbit telehealth partnership
ReviveHealth integrated virtual physical therapy through Orbit Telehealth, consolidating therapy access within a single coordinated care platform alongside primary care, mental health, and pharmacy services. This addresses a structural barrier to rehabilitation—fragmented access—that undermines consistent participation in movement-based interventions critical to maintaining functional capacity and independence across the lifespan.